Rock Creek Pharmaceuticals Inc
Rock Creek Pharmaceuticals — Investor Presentation (July 2014)
46 slides from Rock Creek Pharmaceuticals's investor presentation, Jul 1, 2014

Slide 1: Rock Creek Pharmaceuticals, Inc.
O RockCreek June 30,2014 Pharmaceuticals, Inc.

Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements that will be made during this presentation constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements indude, but are not limited to statements identified by words such as "believes,"

Slide 3: Rock Creek Pharmaceuticals Development
Rock Creek Pharmaceuticals Development Drug development company exploiting the anti-inflammatory and anti-addictive properties of new chemicalentities derived from naturally occurring alkaloids. « Peer-reviewed scientific foundations Continued research on efficacy and tolerability. Large Pre-IND hum

Slide 4: Human Diseases of Inflammation
Human Diseases of Inflammation XN IF Cancer Cardiovascular diseases Pulmonary disease Neurological Intl ti Inflammatory diseases WUE UTES Bowel Disease Autoimmune "4 diseases Diabetes Il Arthritis Q RockCreek

Slide 5: Anatabine
Anatabine « Aminor alkaloid + Found in the solanaceae plant family (potato, pepper, eggplant, tomato), as well as tobacco and nightshade * A cholinergic agonist © RockCreek Pharmaceuticals, Inc.

Slide 6: Anatabine Science
Anatabine Science Anatabine: Reduces inflammatory molecules (iNOS, TNF-«, Cox2, IL-1b, etc.) via reduced gene expression, thus being a potential therapy for inflammatory and immunological diseases. Anatabine Attributes: * Small Molecule + Cholinergic Receptor Activation + Excellent Bioavailability +

Slide 7: Comparison of chemical structures of Anatabine and Nicotine
Comparison of chemical structures of Anatabine and Nicotine (S)-3-(1-Methyl-2-pyrrolidinyl) pyridine YX a" (-)-Nicotine i) N | \ Pe CH N —. H \ (S)-1,2,3,6-Tetrahydro-2,3'-bipyridine \ yj (-)-Anatabine HN Anatabine Nicotine © RockCreek Pharmaceuticals, Inc.

Slide 8: Comparison: Nicotine to Anatabine
Comparison: Nicotine to Anatabine H S cy‘. CY% Sy CH Sy | H Nicotine Anatabine Nicotine, exerts anti-inflammatory effects in multiple cell types and has been shown to benefit various disorders in which inflammation is implicated. Nicotine has a short half life, is toxic (high doses) and most importa

Slide 9

Slide 10: Pentameric Acetylcholine Receptor
Pentameric Acetylcholine Receptor Pentamer nAChR top view (extracellular Pentamer nAChR side view domain) DE (Rock Creek Pharmaceuticals, Inc. 10

Slide 11: ElectroStatic Ribbon Model
ElectroStatic Ribbon Model Acetylcholine Binding at the interface of Anatabine Binding at the interface of a7- a7-nAChR nAChR © RockCreek Pharmaceuticals, Inc.

Slide 12: Acetylcholine Receptor Activation
Acetylcholine Receptor Activation Extracellular Py wy ey Intracellular ge Acetylcholine ., Cellular function Sodium ion

Slide 13: Nuclear Factor Kappa B (NF-KB)
Nuclear Factor Kappa B (NF-KB) NF-kB is a protein complex that controls the transcription of DNA. NF-kB is found in almost all animal cell types and is involved in cellular responses to external stimuli. NF-kB plays a key role in regulating cellular response to inflammation. Specifically, NF-kB cont

Slide 14: NF-kb Signaling pathways
NF-kb Signaling pathways:

Slide 15: Functional Receptor Binding Summary
Functional Receptor Binding Summary nACh Anatabine Potency Function Channel Activity relative to Nicotine a4B2 Full Agonist <<less Addiction (200-fold) a3B4 Partial Agonist < less ? a7 Full Agonist ~ Anti- inflammatory DN () Rock Creek 15 Pharmaceuticals, Inc.

Slide 16: Anatabine: Widespread Anti-inflammatory Properties in pre-clinical models
Anatabine: Widespread Anti-inflammatory Properties in pre-clinical models Suppresses brain inflammation and A-Beta accumulation in animal models of Alzheimer's proves motor n of the spinal cord in animal

Slide 17: Peer Reviewed Published Studies
Peer Reviewed Published Studies Anatabine Lowers Alzheimer’s AB Production in vitro and in vivo + Publication: European Journal of Pharmacology, Sept 2011 + This peer-reviewed article explores the in vitro and in vivo activity of anatabine in Alzheimer's disease. It states that anatabine lowers Alzh

Slide 18: Anatabine dose dependently lowers NF-kB activity in vivo
in vivo (OINL JO 9%) aSB1AJIIN] G44N Anatabine dose dependently lowers NF-kB activity (Control, TNFa and TNFa + Anatabine) 120 90 60 30 0 a CR 18

Slide 19: Effects of Anatabine on Acute Brain Inflammation
Effects of Anatabine on Acute Brain Inflammation Study Design: Water or TNF- OL Anatabine ip intracranial injection injection NF-KB activation

Slide 20: Anatabine Inhibits Brain NF-KB Activation
Anatabine Inhibits Brain NF«KB Activation a2) © > 2 a ~ uw Zz

Slide 21: Experimental Autoimmune Encephalomyelitis
Experimental Autoimmune Encephalomyelitis On day 1, 10 Week-old,C57B16/J Female mice were immunized with 300 ug of murine MOG35-55 (myelin oligodendrocyte glycoprotein). Mice were immediately and at 48 hrs injected IP with 300ug of Pertussis toxin. Mice were randomized in a placebo group (n=15) rece

Slide 22: Incidence of hind limb paralysis in Placebo or Anatabine treated EAE mice
Incidence of hind limb paralysis in Placebo or Anatabine treated EAE mice 70 v a o 2 & 52.5 2 E a a ‘® Placebo (n=15) = 35 @® Anatabine (n=15) S vo 8 § 17.5 a=} iv] £ 0 0 2 4 6 8 10 12 14 16 18 Day After MOG Vaccination DE () Rock Creek 22 Pharmaceuticals, Ino.

Slide 23: Control EAE Placebo EAE Anatabine
Control EAE Placebo EAE Anatabine Reduced nerve damage in Anatabine treated EAE mouse =a Spinal Cord cS = o z Fi a o 3 a g 5 a & g $ q Control (n=6) EAE Placebo (n=15) _ EAE Anatabine (n=14)

Slide 24: Anatabine inhibits Inflammatory Cytokines in Blood of EAE mice
Anatabine inhibits Inflammatory Cytokines in 400 300 xe) 2 5 c ° 1s) . fo} & G 200 ‘= x [o} 2 > U — =] 2 wo nn Blood of EAE mice i Control I EAE Placebo 0) EAE Anatabine

Slide 25: Normalization of Inflammatory Spleen Cytokines in EAE mice by Anatabine
Spleen Cytokine (% of control) Normalization of Inflammatory Spleen Cytokines in EAE mice by Anatabine 500 375 i Control 250 Il EAE Placebo EAE RCP006 125 0 IFNy IL-18 - TNF-a

Slide 26: Proposed Common Mechanism(s) of Action of Anatabine
Proposed. Common Mechanism(s) of Action of Anatabine across different CNS (and non-CNS) conditions Activation of alpha 7 nAchR on microglia (macrophage, monocytes, B-cells, T-cells) v Suppression of inflammatory activity (via & NF-kB) reduced brain reduced inflammatory reduced tissue cytokine releas

Slide 27: Safety Profile
Safety Profile Preclinical safety, toxicity, genotoxicity, teratogenicity evaluations. © 90 Day repeat-dose toxicity, rat studies Early, Multiple Human Studies (> 800 dosed w/ anatabine formulations) + Tobacco Craving/Nicotine withdrawal « Hashimoto's Thyroiditis « Inflammatory Markers, C-Reactive P

Slide 28: Human studies
Human studies Pharmacokinetics «Safety, Tolerability Nicotine Craving «Alzheimer's Disease Hashimoto's Thyroiditis C-reactive protein eInternet-based joint pain questionnaire

Slide 29: Auto-Immune Thyroiditis Human Trial
Auto-Immune Thyroiditis Human Trial » Evaluating the Dietary Supplement, Anatabloc, in Human Thyroid Health, * Primary Outcome: Safety and Tolerability * Secondary Outcome: Anti-thyroid auto- antibodies, thyroid structure, and thyroid function » Enrollment 165 people: 5-visits, 12-week, double- blin

Slide 30: Published Human Results
Published Human Results Journal for Clinical Endocrinology and Metabolism, Oct 31, 2013 ’Anatabine supplementation decreases thyroglobulin antibodies in patients with chronic lymphocytic autoimmune (Hashimoto's) thyroiditis: A randomized controlled clinical trial” (Schmeltz, Blevins, Aronoff, Ozer,

Slide 31: Thyroglobulin antibodies
31 Thyroglobulin antibodies (absolute change over baseline) Reduced Anti-thyroglobulin antibodies in Anatabine treated Thyroiditis patients 20 0 -20 40 -60 p= 0.027 4 Weeks of tre: 8 12 ‘atment % of patients with >20% decrease in TgAb g 80 60 oO HH Placebo 1 Anatabine p= 0.028 p=06ss P= OS1S + 8 12

Slide 32: Joint pain questionnaire of Anatabine dietary supplement users
Joint pain questionnaire of Anatabine dietary supplement users 706 invitees (ordering monthly Anatabloc:) 282 (40%) respondents (selection bias) v 232 (82%) claiming benefit for joint pain Male, Caucasian, ~60 yrs Knees, Shoulder, Back, Wrists/Hands/Fingers 50% > 7yrs duration Clinical Medicine Insi

Slide 33: Anatabine Summary
Anatabine Summary + Pharmacologically active alkaloid * Cholinergic agonist at therapeutically relevant receptors + Preclinical data consistent with anti-inflammatory activity + "Clinical" data with dietary supplement suggests beneficial effects in joint pain and auto-immune thyroiditis + Well toler

Slide 34: Potential Clinical targets for Anatabine
Potential Clinical targets for Anatabine (and related compounds) e Arthritic Conditions (Osteoarthritic Pain) e Inflammatory Bowel Disorders _—_ (Ulcerative Colitis) e Auto-immune disorders (Thyroiditis) e CNS (Alzheimer’s Disease) (Multiple Sclerosis) (Nicotine Addiction) e Dermatology (Psoriasis)

Slide 35: Pipeline
Pipeline Completed extensive in vitro and.in vivo toxicological and pharmacological research on our lead drug candidate. Poised to begin our first Phase 1 Clinical trials in 2014. Candidate Chart Discovery Pre-Clinical Phase? Phase2 Phase hiatal OSTEOARTHAITIS ICLERATIVE COLITIS Pharmaceuticals, Inc

Slide 36: Intellectual Property
Intellectual Property e Issued US patents: Anatabine Citrate - Novel Compound - US Patent: 8,577,999 (Oct 2013) Anatabine: Method of Synthesis - US Patent: 8207346 (June 2012) Anatabine/Yerbe Mate: Use Patent for Weight Loss and Tobacco Craving - US Patent: 8241680 (Aug 2012) ¢ Pending foreign paten

Slide 37: Anti-Inflammatory Market Opportunity
37 ANTI-INFLAMMATORY MARKET OPPORTUNITY + U.S. non steroidal anti-inflammatory market is approximately $15 Billion « Rheumatoid Arthritis market is approximately $8 Billion Global Osteoarthritis (OA) therapeutics market is expected to grow at a rate of 8.7% annually for the next seven years to reach

Slide 38: Financials
Financials Rock Creek Pharmaceuticals, Inc. (Formerly Star Scientific, Inc. ) ‘Three Months Ended March 31, 2014 2013 (Unaudited) (Unaudited) Net sales s 1123 $ 2,507 Less: Product cost of goods sold 457 1,385 Gross profit 666 1,122 Operating expenses: Sales and marketing 825 3,149 General and admin

Slide 39: Financials
Financials The company reported net sales of $1.1 million for the quarter ended March 31, 2014, compared with $2.5 million forthe same period in 2013. (Sales were entirely from nutritional supplement, with the 56% decrease attributable to reduced marketing expenditures resulting in decreased sales v

Slide 40: March 2014 Financing
March 2014 Financing + Financing Package Sale of common stock for $5.1 million Warrant exercise for $4.2 million $5.8 Million credit facility * Use of Funding Po, et Support the IND/CTA applications "™—<\— : ag Phase 1 clinical trials wy Support corporate transition plan Pharmaceuticals, Inc. Ds ()

Slide 41: Management
Management * Dr. Michael! Mullan, MD, Phd., Chairman and Chief Executive Officer Recognized authority on Alzheimer's disease and related disorders. Trained as a physician. Medical degree and PhD in molecular genetics, from London University Inventor on the patents covering the first genetic mutation

Slide 42: Board of Directors
Board of Directors Benjamin M. Dent: CEO of the Dent Consulting Group LLC and an adjunct professor with the St. Louis University graduate program in Entrepreneurial Management. + Mr. Dent previously has served in senior financial management positions with several public and private companies, and al

Slide 43: Risk Factors
Risk Factors ¢ Challenge of intellectual property rights and/or not obtaining additional rights. « FDA regulatory risk and oversight. Clinical studies do not reach desired endpoints. . Legal challenges regarding corporate governance. . Ongoing operating losses, access to cash, sustainable funding an

Slide 44: Projected Milestones
Projected Milestones ast Otr 2015: Phase Two Efficacy Studies Begin 3rd/4th Otr 2014: Phase One Safety, PK, etc. Healthy Volunteers 2nd Otr 2014: ty, PK, Y Preparation and Filing of US IND

Slide 45: Strategic Summary
Strategic Summary: ¢IND - Filed, under FDA review * Target disease evaluation - Under review * Clinical site evaluation for Phase 1- Identified * Corporate Transition - Substantially Completed Pharmaceuticals, Inc. DI (Rock Creek 45

Slide 46: Rock Creek Pharmaceuticals, Inc.
© RockCreek — Pharmaceuticals, Inc. June 30, 2014
Source: SEC EDGAR · 8-K filed Jul 1, 2014




